Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory cytokines in two cohorts of SCLC patients before and during treatment with chem...

Full description

Bibliographic Details
Main Authors: Max Hardy-Werbin, Pedro Rocha, Oriol Arpi, Álvaro Taus, Lara Nonell, Xavier Durán, Xavier Villanueva, Deborah Joseph-Pietras, Luke Nolan, Sarah Danson, Richard Griffiths, Miguel Lopez-Botet, Ana Rovira, Joan Albanell, Christian Ottensmeier, Edurne Arriola
Format: Article
Language:English
Published: Taylor & Francis Group 2019-06-01
Series:OncoImmunology
Subjects:
small cell lung cancer
ipilimumab
cytokines
immunotherapy
biomarkers
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1593810

Internet

http://dx.doi.org/10.1080/2162402X.2019.1593810

Similar Items